20
Participants
Start Date
October 28, 2020
Primary Completion Date
July 28, 2022
Study Completion Date
July 28, 2022
RO7293583
RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
Tocilizumab
Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
Obinutuzumab
If implemented, it will be given either on D-7 or D-7 and D-6.
Adalimumab
If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
UZ Antwerpen, Edegem
Herlev Hospital; Afdeling for Kræftbehandling, Herlev
Peter Maccallum Cancer Institute; Clinical Trial Unit, Melbourne
UZ Leuven Gasthuisberg, Leuven
Memorial Sloan-Kettering Cancer Center, New York
Thomas Jefferson University Hospital;Medical Oncology, Philadelphia
Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid
Clinica Universitaria de Navarra, Pamplona
Sarah Cannon Research Institute, Nashville
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia
Dana Farber Cancer Institute, Boston
The Ottawa Hospital - General Campus, Ottawa
Princess Margaret Cancer Center, Toronto
Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Hoffmann-La Roche
INDUSTRY